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A humanized mouse model
identifies key amino acids for low
immunogenicity of H7N9 vaccines
Yamato Wada1,2, Arnone Nithichanon1,3, Eri Nobusawa4, Leonard Moise5,6, William D. Martin6,
Norio Yamamoto4,7, Kazutaka Terahara1, Haruhisa Hagiwara8, Takato Odagiri4, Masato
Tashiro 4, Ganjana Lertmemongkolchai3, Haruko Takeyama2, Anne S. De Groot5,6,
Manabu Ato1 & Yoshimasa Takahashi1
Influenza vaccines of H7N9 subtype are consistently less immunogenic in humans than vaccines
developed for other subtypes. Although prior immunoinformatic analysis identified T-cell epitopes
in H7 hemagglutinin (HA) which potentially enhance regulatory T cell response due to conservation
with the human genome, the links between the T-cell epitopes and low immunogenicity of H7 HA
remains unknown due to the lack of animal models reproducing the response observed in humans.
Here, we utilized a humanized mouse model to recapitulate the low immunogenicity of H7 HA.
Our analysis demonstrated that modification of a single H7 epitope by changing 3 amino acids so
that it is homologous with a known H3 immunogenic epitope sequence significantly improved the
immunogenicity of the H7 HA in the humanized mouse model, leading to a greater than 4-fold increase
in HA-binding IgG responses. Thus, we provide experimental evidence for the important contribution of
this H7-specific T cell epitope in determining the immunogenicity of an influenza vaccine. Furthermore,
this study delineates strategies that can be used for screening and selecting vaccine strains using
immunoinformatics tools and a humanized mouse model.
Influenza virus infections continuously cause severe morbidity and mortality, contributing to 250,000–500,000
annual deaths worldwide1. Vaccines that evoke memory antibody responses with virus-neutralizing activity are
the best prophylaxis against influenza virus infection2. Unfortunately for vaccine developers, influenza A virus
has multiple subtypes related to the sequence variation of two key envelope antigens, the hemagglutinin (HA) and
neuraminidase (NA) proteins. Seasonal strains of the H1N1 and H3N2 subtypes persist in human populations by
constantly acquiring mutations (antigenic drift) which enable them to escape from protective HA-binding antibodies3, 4. As a result, almost all adults have been exposed to seasonal influenza viruses and possess pre-existing
immunity, primarily consisting of memory B cells, long-lived plasma cells, CD4+ memory T cells, and CD8+
memory T cells.
Due to the existence of immunological memory, seasonal influenza vaccines can be given as a single dose
annually boosting humoral memory responses5. Conventional formulations of the seasonal vaccines (split-virion
type) drive the differentiation of affinity-matured memory B cells into plasma cells that produce high-affinity
antibodies with the help of CD4+ memory T cells6. In contrast, newly emerging viruses were believed not to boost
humoral memory responses as effectively as seasonal vaccines due to the absence of pre-existing memory B and/
or CD4+ T cells. However, this classical view was recently revised after the analysis of human immune responses
against pandemic H1N1 (pH1N1) vaccines; protective immune responses were observed, despite the lack of prior
exposure7–10.
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Split-virion pH1N1 vaccines containing 15 μg HA unexpectedly elicited hemagglutination inhibition antibody
titers >1:40 in 94.3–98% of healthy adults7–10 with an estimated 87.3% effectiveness11. These clinical data demonstrated that pH1N1 vaccines were able to drive protective immune responses after a single dose of unadjuvanted
vaccine, despite the lack of previous exposure to homologous virus infection. One explanation for this observation was that a large number of T-cell epitopes were found to be conserved between pH1N1 and seasonal H1/H3
HAs, and that exposure to pH1N1 effectively boosted pre-existing CD4+ memory T cells that had been primed
by exposure or vaccination with seasonal influenza strains12–15. Moreover, the numbers of CD4+ memory T cells
were found to correlate well with the magnitude of the antibody responses following pH1N1 vaccination16 and
infection17. Based on these observations, it is generally accepted that pH1N1 vaccination leads to the expansion
of the pre-existing CD4+ memory T cells to cross-conserved HA epitopes, supporting the rapid production of
HA-binding antibodies.
Similarly, the efficacies of vaccines against other newly emerging influenza subtypes are expected to be related
to the presence of cross-reactive CD4+ memory T cells that are generated by seasonal viruses and/or vaccines.
For example, avian influenza H5N1 and H7N9 viruses share a number of T cell epitopes with seasonal viruses18–20
as do pH1N1 viruses12–15. However, vaccines against both H5N1 and H7N9 are poorly immunogenic, resulting in only 10–26% (H5N1) and 1% (H7N9) seroconversion rates, respectively, after a single vaccination with
non-adjuvanted formulations21–23. Clinical trials of H7N9 vaccines have required the use of adjuvant to increase
the seroconversion rates to an acceptable level. Even when two doses of H7N9 vaccine were administered with
adjuvant to generate new memory T cells to the novel virus, only 47% of subjects sero-converted in a recent Phase
II clinical trial23. The development of neutralizing antibodies to H7N9 is also delayed in H7N9-infected humans
when compared to the typical immune responses to other influenza virus infections and IgG avidity to H7N9 HA
is significantly lower24. In clinical trials of other H7 subtypes, an attenuated H7N1 vaccine elicited low HI titers25,
and an inactivated subunit H7N7 vaccine was poorly immunogenic26.
These observations suggest that additional antigenic determinants other than cross-reactive T-cell epitopes
may regulate vaccine-induced memory responses. In support of this concept, the previous immunoinformatics
analysis identified H7-specific T-cell epitopes that were highly conserved with the human genome (human-like),
an in silico signature that could potentiate regulatory T cell (Treg) responses27. H7 peptides comprising the
human-like epitopes expanded CD25highFoxP3+CD4+ T cells in human PBMC cultures in vitro, and that
co-incubation of the H7 peptides could suppress the effector T-cell responses induced by other H7-immunogenic
peptides28. However, in vivo evidence supporting links between H7-specific T-cell epitopes and the low immunogenicity of H7 HA has been limited to date.
Here, we established a humanized mouse model to recapitulate serological memory responses following influenza vaccination. Our data demonstrated that the substitution of a single H7-specific T cell epitope in the H7 HA
protein with an immunogenic H3 consensus sequence significantly improved the immunogenicity of the vaccine
in a humanized mouse model. These results provide strong experimental evidence of the contribution of this
H7-specific epitope to the lack of immunogenicity of H7N9 vaccines, as was previously proposed28.

Results

H7N9 and H3N2 vaccines show comparable immunogenicity in naïve mice. There are two phylogenic groups in HA of influenza A viruses; group 1 (e.g. H1 and H5 subtypes) and group 2 (e.g. H3 and H7
subtypes). First, we compared the immunogenicity of inactivated whole-virion vaccines between phylogenetically related H3N2 and H7N9 subtypes in the same group 2 using inbred BALB/c mice. Each group of mice was
primed and boosted intraperitoneally at 3-week intervals with a non-adjuvanted formulation of the same vaccine.
Immune sera were collected at day 10 after boost as shown in Fig. 1a. V15–5 monoclonal antibody, which binds
to both H3 and H7 subtypes with similar binding affinity, was used as the standard antibody for quantification
of antibody titers, thus allowing for the direct comparison of antibody titers to both subtypes in parallel. At day
10 after boosting, the H7N9 whole-virion vaccines elicited anti-HA IgG titers at slightly but significantly higher
levels than the H3N2 whole-virion vaccines (Fig. 1b), although the numbers of anti-HA IgG plasma cells were
comparable (Fig. 1c).
Whole-virion vaccines contain other non-HA viral proteins or specific viral particle structures which can
potentially influence their immunogenicity. Therefore, we prepared baculovirus-produced HA protein, which
is a vaccine formulation approved for human use. The data obtained with the HA protein showed that H3 and
H7 HAs were similarly immunogenic to elicit comparable levels of anti-HA IgG titers and plasma cells in inbred
BALB/c mice (Fig. 1d and e). The implication of these studies is that standard mouse models could not replicate
the low immunogenicity of H7 HA observed in clinical studies, because BALB/c mice were naïve to both H3
and H7 HAs, while human populations were naïve to H7 HA but were immune to H3 HA. However, it remains
possible that H7-specific T-cell epitopes identified by the previous analysis28 modulate the immunogenicity of
H7 HA at some extent and this question is better addressed in the models that mimic HLA-restricted immune
responses in humans.
Humanized mouse models can recapitulate memory antibody responses in humans after influenza vaccination. We therefore decided to determine whether a humanized mouse model could be used

to reproduce vaccine-boosted memory responses in humans which are crucially controlled by HLA-restricted
interactions with pre-existing memory T and B cells. The NOD/SCID/Jak3−/− (NOJ) mouse strain has defective
T and B cell development through a SCID mutation as well as impaired NK cell development due to the lack
of IL-2R-mediated Jak3 signaling. This mouse strain has been successfully used as a recipient for transplanted
human cells29, 30. As expected, we observed that NOJ mice transplanted with human peripheral blood mononuclear cells (PBMCs) produced human anti-HA IgG antibodies after vaccination with several doses (10, 30,
and 90 μg per mouse) of H3N2 whole-virion vaccines (Fig. 2a and b). To reduce the possible donor-to-donor
Scientific Reports | 7: 1283 | DOI:10.1038/s41598-017-01372-5
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Figure 1. Memory antibody responses elicited by both H7N9 and H3N2 vaccines in naïve mice. As shown
in experimental scheme (a), BALB/c mice were immunized intraperitoneally twice at a 3-week interval with
10 μg of inactivated whole-virion vaccines (b,c) or with recombinant HA proteins (d,e) derived from H7N9 and
H3N2 strains. Ten days after boost immunization, sera and splenocytes were collected and analyzed for anti-HA
IgG titers using ELISA (b,d) and anti-HA IgG plasma cells using ELISPOT assay (c,e). Each circle represents the
result from an individual mouse. The difference between H3N2 and H7N9 vaccines was statistically evaluated
by a Mann-Whitney test. The data shown are representative of two independent experiments.
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Figure 2. Humanized mouse models to recapitulate memory antibody responses after influenza vaccination.
(a) NOJ mice were reconstituted with human PBMCs and 24 h later were boosted intravenously with influenza
vaccines. At day 10 post-vaccination, sera were collected and analyzed for anti-HA IgG titers by ELISA as
shown in a. (b) NOJ mice were boosted with different doses of H3N2 whole-virion vaccines and the anti-HA
IgG titers in serum samples were estimated by ELISA. The data from three donors are presented. (c) NOJ
mice were boosted with 90 μg of either whole-virion or recombinant HA vaccines derived from the H3N2
subtype. Anti-HA IgG titers in serum samples were estimated by ELISA. Each circle represents the result from
an individual mouse. The data shown are representative of two independent experiments. (d) Avidity index
of anti-HA IgG antibodies in the sera of the humanized mice and vaccinated donors were plotted. The avidity
indices of mutated (open) or germline-reverted (filled) V15–5 monoclonal antibodies were also plotted. Each
circle represents the result for an individual mouse.

variation, we maximized the antibody response by using 90 μg per mouse as the vaccination dose, even though
this dose is higher than the dose that is usually applied in standard mouse models. Similar experiments were
performed using a recombinant H3 HA protein resulting in recall responses comparable to those obtained with
whole-virion vaccines (Fig. 2c). To further confirm the contribution of recall responses on elicited HA-binding
antibodies, we examined antibody avidity indices by using a modified ELISA to dissociate plate-bound,
low-affinity antibodies selectively via treatment with 7 M urea (Fig. 2d)31. Mutated or germline-reverted forms
of V15–5 monoclonal antibodies were assayed in parallel as controls. We also determined the avidity indices of
serum antibodies from vaccinated donors as positive controls. The data clearly demonstrate that humanized mice
developed antibody responses with equivalent avidity indices to those from serum of vaccinated donors and
affinity-matured monoclonal antibody. Therefore, our results demonstrate that this humanized mouse model can
reproduce vaccine-boosted memory responses and the development of high affinity antibody responses, and that
it can be used to evaluate the human immunogenicity of influenza vaccines in vivo.
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H7 HA is poorly immunogenic in a humanized mouse model.

Having demonstrated that the
humanized mouse model could reproduce human memory responses against influenza vaccines, we then examined whether immunization of the mice with H7N9 vaccines would recapitulate previous observations that
the vaccines were poorly immunogenic in humans, as demonstrated repeatedly in clinical trials23, 32, 33. Pairs of
humanized mice were prepared using PBMCs from the same donor. One mouse from each pair received H3N2
whole-virion vaccine (control group) and the second mouse received H7N9 whole-virion vaccine (experimental
group). Side-by-side analysis of each pair of humanized mice from the same donor increased the sensitivity of
the assay by reducing the negative impact of donor-to-donor variability caused by different genetic backgrounds
and immune histories. Indeed, there was considerable intragroup variability in the antibody response elicited
by both control (H3N2) and experimental (H7N9) groups (Fig. 3a and b). Despite this variability, significantly
lower antibody responses were observed in the H7N9-vaccinated groups (Fig. 3a and b) compared to those in
the H3N2-vaccinated control group, with only two mice showing similar or higher responses against the H7N9
vaccines. We also performed the same study using recombinant H3 and H7 HA vaccines to exclude the possibility
that other internal viral proteins present in the whole-virion vaccines could influence the HA-binding antibody
response due to the utility of T cells responding to non-HA antigens34. The recombinant HA vaccines completely
reproduced the results observed with whole-virion vaccines, in that H7 HA vaccination was only able to induce
weak HA-binding antibody recall responses (Fig. 3c and d), as compared to H3 HA vaccination in the mice transplanted with PBMCs from the same donor. From these results, we concluded that this humanized mouse model
can recapitulate the low levels of HLA-restricted antibody response elicited by H7 HA, as observed in clinical
trials.
As previously noted, one explanation for the poor immunogenicity of H7 HA in human PBMC-transplanted
NOJ mice is lack of prior H7N9 exposure in humans, which contrasts with greater levels of antibodies against
H3 HA due to the pre-existing immunity. To assess the contribution of prior exposure to H3 HA, NOJ mice
were transplanted with murine lymphocytes from H3N2-exposed mice instead of human PBMCs. Consistent
with the data from human PBMC-transplanted NOJ mice, H7 HA vaccination of NOJ mice transplanted with
H3N2-primed mouse lymphocytes elicited low anti-H7 HA IgG responses (Fig. 3e,f). Given the comparable
immunogenicity of H3 and H7 HA in naïve mice (Fig. 1), these results suggest that the lack of immune history
to H7 HA substantially contributes to low antibody responses to H7 HA vaccines in NOJ mice transplanted with
H3N2-primed lymphocytes.

Mutation of H7-specific T-cell epitope improves the immunogenicity of H7 HA in a humanized
mouse model. Previous immunoinformatics analysis identified H7-specific T-cell epitopes that may poten-

tially enhance Treg responses in HLA-restricted manner, which could also affect the magnitude of antibody
responses elicited by vaccines28. One such T cell epitope corresponding to amino acid residues 315 to 328 in
the H7 HA (Fig. 4a) was previously shown to expand FoxP3+ Treg cells in PBMCs after in vitro stimulation,
which in turn, correlated with the partial suppression of effector T-cell responses against other H7N9 peptides by
co-incubation with this peptide28. In order to assess a possible contribution of the H7-specific T-cell epitopes on
the observed low immunogenicity of H7 HA, we designed and generated a H7 HA mutant protein (designated as
Opt1 H7 HA) containing only 3 amino acid replacements, which converted the H7 epitope into the sequence of
an immunogenic H3 epitope found in the same region of the H3 HA protein (Fig. 4a).
The Opt1 H7 HA protein was produced in a baculovirus expression system (same as for wild-type H7 HA),
and then assayed for binding against polyclonal H7 HA-binding IgG antibodies present in the serum of healthy
volunteers to evaluate the effect of the amino acid substitutions on HA antigenicity (Fig. 4b). Opt1 H7 HA and
wild-type H7 HA protein was equally well recognized by polyclonal H7 HA-binding IgG antibodies in human
sera, indicating that B-cell epitopes remained intact in Opt1 H7 HA. We then examined T-cell related effects that
could be caused by the three amino acid replacements introduced in Opt1 H7 HA. As demonstrated in Fig. 3,
pairs of humanized mice were prepared using PBMCs from the same donor. One of the mice from each pair was
immunized with the wild-type H7 HA vaccine (control group) and the other mouse with Opt1 H7 HA vaccine
(experimental group). We observed that Opt1 H7 HA vaccines induced significantly higher levels of anti-HA
IgG responses, resulting in >4-fold increases in antibody titers compared to wild-type H7 HA vaccines (Fig. 4c
and d). Intriguingly, half of the humanized mice responded better to Opt1 H7 HA, while another half responded
to Opt1 H7 HA in a range similar to wild-type H7 HA. The high and low responders may be explained by HLA
haplotypes or differential status of memory T cell responses/Treg responses in donors. Further investigations are
required to address these possibilities.
To determine whether this result was specific to HLA-restricted immune responses in humans, the same set
of vaccines was administrated into NOJ mice that had received H3N2-primed murine lymphocytes as previously
described (Fig. 3e). Despite prior exposure to H3N2, we did not observe any significant difference in boosting
ability between wild-type H7 HA and Opt1 H7 HA (Fig. 4e and f), suggesting that the difference observed in
the human PBMC-transplanted mice were related to HLA-restricted (and not mouse MHC-restricted) immune
responses rather than to previous exposure to H3 HA. Collectively, these results strongly support the notion that
H7 HA is poorly immunogenic, at least partly, due to the presence of HLA-restricted human-like T cell epitopes
and/or the absence of immunogenic T-cell epitope, as was predicted by immunoinformatics analysis28.

Discussion

Unexpected clinical findings from non-adjuvanted pH1N1 vaccines have contributed to a revision of classical
views of memory antibody responses to influenza vaccines. Cross-reactive CD4+ memory T cells have been identified as key determinants of immunogenicity for pH1N1 vaccines and viruses16, 17. It has been more difficult to
explain the poor immunogenicity of H5N1 and H7N9 vaccines, since these strains do share cross-conserved
T-cell epitopes with seasonal influenza strains to some extent18–20. The results presented in this paper provide
Scientific Reports | 7: 1283 | DOI:10.1038/s41598-017-01372-5
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Figure 3. Low immunogenicity of H7N9 vaccines revealed in a humanized mouse model. Pair of humanized
mice were prepared from the same donors, boosted intravenously with 90 μg of either whole-virion (a,b) or
recombinant HA (c,d) vaccines and assayed for human anti-HA IgG titers (a,c) at day 10 post-vaccination using
V15–5 monoclonal antibody as standard. Fold differences in anti-H7 versus H3 IgG titers are plotted in the right
panel (b,d). The difference in antibody responses between H3N2 and H7N9 vaccinated groups was statistically
evaluated by a Wilcoxon matched-pairs signed rank test. Each circle represents the result from an individual
mouse. (e,f) NOJ mice were reconstituted with H3N2-primed mouse splenocytes and then boosted with 90 μg of
whole-virion vaccines. Mouse anti-HA IgG titers were assessed at day 10 post-vaccination. The difference between
H3N2 and H7N9 vaccinated groups was statistically evaluated by a Wilcoxon matched-pairs signed rank test.
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Figure 4. Enhanced immunogenicity of Opt1 H7 HA independently of B-cell epitopes. (a) H7 T-cell epitope (315–
328) and H3 epitope (322–335) in the corresponding region are presented. Opt1 H7 HA was designed to reduce the
levels of molecular mimicry in the H7 T-cell epitope by substitution with an immunogenic H3 epitope. Key amino
acid residues that differ between H7 and H3 are highlighted in red. (b) Wild-type H7 HA (open) and Opt1 H7
HA (filled) were compared for recognition by polyclonal H7 HA-binding IgG antibodies present in human serum
using ELISA. (c) Pair of humanized mice were prepared from the same donors, boosted intravenously with 90 μg
of H7 or Opt1 H7 HA vaccines, and assessed for human anti-HA IgG titers at day 10 post-vaccination using V15–5
monoclonal antibody as standard. The difference between H7 and Opt1 H7 HA vaccinated groups was statistically
evaluated by a Wilcoxon matched-pairs signed rank test. Each circle represents the result from individual mouse.
(d) Fold differences in anti-Opt1 versus H7 HA IgG titers are plotted. (e) NOJ mice were reconstituted with H3N2primed mouse splenocytes and then boosted with 90 μg of H7 or Opt1 H7 HA vaccine. Thereafter, mouse anti-HA
IgG titers were assessed at day 10 post-vaccination. The difference between H7 and Opt1 H7 HA vaccinated groups
was statistically evaluated by a Wilcoxon matched-pairs signed rank test. Each circle represents the result from
individual mouse. (f) Fold differences in anti-Opt1 versus H7 HA IgG titers are plotted.
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experimental evidence that H7-specific T cell epitopes significantly affect the immunogenicity of H7 influenza
vaccines and suggest two compatible possibilities for this observation. One is molecular mimicry that negatively
impacts on the immunogenicity of H7 HA through immune tolerance and the other is a lack of cross-conserved
effector T-cell epitopes that enhances the immunogenicity. The previous study supports the former possibility,
as the epitope sequence targeted for modification expanded CD25highFoxP3+CD4+ T cells in human PBMC cultures in vitro, and co-incubation of the epitope could suppress effector T-cell responses stimulated by other H7
immunogenic peptides28. The relative contribution of seasonal influenza epitopes newly introduced into H7 HA
to improve antibody responses remains an important question.
This paper also demonstrates the usefulness of NOJ mice reconstituted with human PBMCs for evaluating the
immunogenicity of influenza vaccines. A similar humanized mouse system using SCID/SCID mice as recipient
has been successfully applied to the analysis of humoral recall responses to pneumococcal vaccines35; however, to
our knowledge, this is the first report focusing in vivo recapitulation of the comparative immunogenicity of influenza vaccines observed in humans. One caveat of this mouse system is that anti-HA IgG antibody titers in human
cell-transplanted NOJ mice (0.35 μg/ml) were lower than those in mouse cell-transplanted NOJ mice (14 μg/
ml) (Fig. 3). Possibly due to the low recall responses, human T-cell responses in the same humanized mice were
below the detection limit (data not shown), hampering further analysis of T cell responses that are responsible
for low immunogenicity of H7 HA. Because Opt1 H7 HA showed comparable immunogenicity to wild-type H7
HA in murine cell-transplanted NOJ mice (Fig. 4e and f), we surmise the increased antibody responses observed
in human cell-transplanted mice may be attributed to species-specific events such as differential specificities,
frequencies, and functions of human CD4+ T cells. In this context, in vitro human PBMC cultures in a prior study
showed that wild-type H7-specific epitope (315–328) expanded CD25highFoxP3+CD4+ Treg cells and reduced
IFN-γ secretion from T cells stimulated with other H7 epitopes28. Thus, substitution of the H7-specific epitope
with a highly conserved H3 epitope under HLA restriction could avoid Treg induction by the wild-type H7 and
boost CD4 T cell responses in human cell-transplanted mice.
Cognate interaction of memory T and B cells mediated by HLA-restricted T-cell epitope is one of the most
important factors regulating the magnitude and quality of recalled memory responses36. At least one subset of
memory T and B cells, called central memory, circulates in the blood, making it possible to recapitulate the
cognate interactions between human memory T and B cells in mice using a humanized mouse model system37.
Indeed, we found that the affinity maturation of elicited antibody responses in humanized mice was similar to
those in vaccinated donors, supporting the idea that the reproduced responses are mainly composed of recall
responses rather than primary responses. Thus, the humanized NOJ mouse model appears to be useful for vaccine studies, since it can mimic the human recall responses to protein-based influenza vaccines, making it a
suitable model for use in preclinical trials. While it is conceivable that innate cells and stromal cells also play
roles in enhancing recall responses38, the effects of these cells are largely modulated by non-protein composition
of vaccines, especially the ligands of pattern-recognition receptors, which are not included in HA protein-based
vaccines.
The study may also introduce the concept of host mimicry into influenza viruses. Many chronically infecting
viruses, such as Epstein-Barr virus, herpes simplex virus, human immunodeficiency virus, hepatitis C virus, and
cyotomegaloviruses, may avoid or attenuate effector T-cell responses by mimicking to a self-antigen, thereby limiting effector T-cell responses or causing the expansion and activation of Treg cells39, 40. A comprehensive analysis
of the full genomes of these human pathogens demonstrated that these viruses contained fewer T-cell epitopes
and exhibited higher cross-conservation with autologous antigens than did acutely infecting Ebola and Marburg
viruses41. Furthermore, the immunosuppressive effects of human-like T cell epitopes have been experimentally
confirmed for hepatitis C virus (HCV); in vitro stimulation of PBMCs by self-mimicking HCV peptides expanded
Treg cells42, as was also the case for H7N9 epitopes. Thus, it is tempting to speculate that human-like epitopes
found in H7 HA is an explanation for reduced H7N9 vaccine efficacy in humans and humanized mice.
While the prevalence of human-like epitopes in human commensals can be interpreted as a mean of viral
escape, the presence of human-like epitopes in an avian-origin influenza virus is more difficult to explain. To date,
human-to-human transmission of H7N9 is quite rare, as the virus is not fully adapted to humans43, 44. One explanation for the presence of human-like epitopes could be that these epitopes contribute to the success of H7N9
propagation in their usual hosts. Models for avian MHC are not yet available, thus it is difficult to determine
whether epitopes like the one validated here contributes to immune escape by H7N9 in chickens or other birds.
Future serological studies in humans, other mammals, and poultry, as well as additional investigation into the
potential contribution of Treg responses in non-human hosts, may shed light on the origin of H7-specific T-cell
epitopes that affect the immunogenicity of influenza vaccines.

Methods

Immunoinformatic design of Opt1 H7 HA. The amino acid sequence of the influenza A/Shanghai/2/2013

HA (H7) was obtained from GISAID (www.gisaid.org). The retrieved sequence was parsed into overlapping
9-mer frames and screened for the presence of predicted class II restricted T cell epitopes using the EpiMatrix
system45. ClustiMer, an algorithm used to identify short amino acid sequences containing multiple HLA binding
motifs, was used to identify potential T cell epitope clusters contained within the H7 HA sequence46. Finally, the
JanusMatrix algorithm was used to identify putative T cell epitopes contained within H7 HA which share TCR
contacts with putative epitopes present in the human genome47.

Vaccine preparation. NIBRG-268 (A/Anhui/1/2013, H7N9) virus was provided by the National Institute
for Biological Standards and Controls. IVR-165 (A/Victoria/361/2011, H3N2) virus was provided by the
Commonwealth Serum Laboratories. Both viruses were propagated on embryonated chicken eggs and purified
through a 10–50% sucrose gradient as previously described48. For inactivation, purified viruses were treated with
Scientific Reports | 7: 1283 | DOI:10.1038/s41598-017-01372-5
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0.1% formalin at 4 °C for a week and used as inactivated whole-virion vaccines. Recombinant HA protein was
produced in a baculovirus expression system (Clontech) as previously described49.

Mice and vaccination. BALB/c mice were purchased from Japan SLC and NOD/SCID/Jak3−/− mice were
kindly provided by Dr. S. Okada (Kumamoto University) and maintained in our institute. All mice were maintained under SPF condition and used at 8–15 weeks of age. BALB/c mice were intraperitoneally immunized
with whole-virion or HA vaccines (10 μg per mouse) and boosted by the same dose of vaccines. At day 10 after
boosting, sera were recovered from tail veins and subjected to ELISA for measuring anti-HA IgG antibody titers.
Spleen cells were also recovered after boosting and then evaluated by ELISPOT assay for enumerating anti-HA
IgG plasma cells. In some experiments, BALB/c mice were intranasally infected with H3N2 (X31) virus as previously described49 and were used as the source of H3N2-primed splenocytes at more than 2 months after infection.
The humanized mouse model was developed as follows; heparinized peripheral blood was obtained from
healthy donors with written informed consent and PBMCs were freshly isolated by density centrifugation using
Ficoll-Hypaque (GE Healthcare). Two mice were intravenously transplanted with 2–5 × 107 PBMCs from each
donor. Twenty-four hours after transplantation of PBMCs, the mice were intravenously vaccinated and the
serum and spleens were collected at day 10. In some experiments, the splenocytes from H3N2-primed mice
were used for transplantation. All animal experiments were approved by the animal experimental committees
of the National Institute of Infectious Diseases, Japan, and performed in accordance with the guidelines of the
Institutional Animal Care and Use Committee. The studies using human samples were approved by Institutional
Ethics Committee of Human Experimentation and performed in accordance with the Ethical Guidelines for
Medical and Health Research Involving Human Subjects in Japan.
ELISA and ELISPOT. For the detection of anti-HA plasma cells with ELISPOT assay, nitrocellulose membranes were coated with 10 μg/mL recombinant HA, and cells were incubated on the membranes for 3 h at 37 °C.
After the cells were washed off, the membranes were incubated with anti-mouse IgG–HRP (Southern Biotech).
HRP activities were visualized as previously described49. For the detection of anti-HA antibody titers, ELISA was
performed with anti-mouse IgG-HRP, or anti-human IgG-HRP as previously described50. The avidity index was
calculated by dividing anti-HA IgG antibody titers resistant to 7 M urea treatment (15 min) by total anti-HA IgG
antibody titers. For standard antibodies, we used IgG1 monoclonal antibody (V15–5) with comparable binding
to H3 and H7 HA.
Statistical analysis.

Statistical significance was determined using a two-tailed, nonparametric
Mann-Whitney test or Wilcoxon matched-pairs signed rank test. P-values less than 0.05 were considered
significant.
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